Bill To Lower Pay Of Out-Of-Network Physicians, Costs Delayed To 2020
A bill meant to stop out-of-network "surprise billing" may have stalled but is likely to make a reappearance when Congress reconvenes next year according to lawmakers and experts. Despite support in key Senate and House committees, the bill hit a wall when lawmakers introduced an alternative version in the House Ways and Means Committee late in the legislative session.
You may also be interested in...
A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.
US Insurers, Hospitals, Medtech Industry Say Transparency Rule Touted In President’s Speech Is Anticompetitive
US President Donald Trump in his State of the Union address on 4 February touted his 2019 Price Transparency executive order calling on federal agencies to require private hospitals and insurers to publicly reveal the costs of hundreds of their device-related procedures and lab tests – as well as insurers’ negotiated rates for them – so patients can shop for their own health care. But industry maintains the resulting rules out of the Centers for Medicare and Medicaid Services are “anticompetitive,” and a coalition of hospital groups is suing the Department of Health and Human Services to stop their implementation.
2020 Outlook: US Congress Will Address Surprise Billing, Ratify USMCA, Conduct More Medtech Safety Oversight
Congress was able to approve a permanent medical device tax repeal and pass a “LAB Act” bill favorable to the diagnostic industry in 2019. But what device-related legislation is ahead in 2020? Medtech Insight takes a look at some of the medtech bills and draft legislation likely to affect manufacturers pending in late 2019 that are likely to be reviewed – and perhaps approved – in 2020.